2025-524693-42-00RecruitingPhase 1
A study to see how RO7763505 works and how safe it is when given to healthy people and people with stable heart disease
F. Hoffmann-La Roche AG2 sites in 1 country196 target enrollmentStarted: March 15, 2026Last updated:
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- F. Hoffmann-La Roche AG
- Enrollment
- 196
- Locations
- 2
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Trial Information System - TISL
Scientific
F. Hoffmann-La Roche AG
Study Sites (2)
Loading locations...
Similar Trials
Recruiting
Phase 1
A study investigating the safety of RO7795074, a new compound that may potentially be used in the treatment of type 1 diabetes, and the effect of RO7795074 on how the body processes pitavastatin2025-521921-34-00Genentech Inc.32
Recruiting
Phase 1
A study investigating the safety of RO7795081 and the effect of RO7795081 on how the body processes different approved medications. RO7795081 is a new compound that may potentially be used in the treatment of type 2 diabetes and weight control2024-519277-18-00F. Hoffmann-La Roche AG40
Completed
Phase 1
A trial to learn if REGN7999 is safe and well tolerated, and how it works in the body of healthy participants.2022-500398-15-00Regeneron Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc.64
Recruiting
Phase 1
A Phase I Study of RO7589831 Alone and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors2023-503170-20-01F. Hoffmann-La Roche AG46
Recruiting
Phase 1
A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants with Type 2 Diabetes Mellitus(T2DM) and Overweight or Obesity2025-521401-41-00F. Hoffmann-La Roche AG30